ArticleRare tumors2026
Pulmonary carcinoid harboring a
Article in Rare tumors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary carcinoids are the pulmonary counterparts of gastrointestinal neuroendocrine tumors (NETs) G1-2. They may cause distant metastasis, leading to a poor prognosis, and requiring chemotherapy. Reports on cases harboring driver gene mutations remain limited. A man in his late 60s visited to JA Onomichi General Hospital because he was suspected of lung cancer. Positron emission tomography/computed tomography (PET/CT) showed a 24-mm nodule in the right upper lobe with abnormal ^18F-fluorodeoxyglucose uptake, and bronchoscopic examination revealed adenocarcinoma. Surgery was planned for stage IA3 lung adenocarcinoma; however, intraoperative findings demonstrated pleural dissemination, and the procedure was terminated as an exploratory thoracotomy. Pathological examination of tissue obtained from the pleural dissemination showed features consistent with NET G2, confirming a diagnosis of atypical carcinoid. Ten months after treatment with carboplatin plus etoposide, salvage surgery consisting of right upper lobectomy and resection of pleural dissemination was performed. Histopathological examination revealed a papillary adenocarcinoma adjacent to a NET G2. Three months after surgery, CT revealed a metastatic lesion in the retrohepatic segment. Histological examination of the liver tumor obtained via laparoscopic hepatectomy confirmed a NET G2 without adenocarcinomatous components. Four months after hepatectomy, PET/CT demonstrated multiple lymph node metastases. The patient was treated sequentially with carboplatin plus etoposide, everolimus, and amrubicin, however, the liver metastases progressed. A liver tumor biopsy was performed for comprehensive genomic profiling (CGP). The biopsy specimen revealed metastatic NET G2. FoundationOne CDx testing identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.